Cancer focus in China, Hansoh Pharma’s Ameile faces fresh competition

Hansoh Pharma’s EGFR inhibitor Ameile remains a key lung cancer therapy in China, but newer targeted drugs are closing in. What the tablet offers today in dosing, survival data and pricing – and how the franchise fits into Hansoh’s broader oncology push.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 2:09 AM ET. Details in the imprint.

Hansoh Pharma’s third-generation EGFR inhibitor Ameile, approved in China for certain forms of non-small cell lung cancer, is under growing scrutiny as rival targeted therapies reach the market and treatment standards shift toward earlier intervention and combination regimens.

What Ameile does for EGFR-mutated lung cancer patients

Ameile (almonertinib) is an oral tyrosine kinase inhibitor designed to target EGFR T790M and other sensitive mutations in locally advanced or metastatic non-small cell lung cancer after progression on earlier EGFR drugs, and it has become one of Hansoh Pharma’s key oncology brands in China. Hansoh Pharma’s official product information describes once-daily dosing and mutation-focused labeling as core to the medicine’s positioning.

In clinical studies conducted in Chinese patients, Ameile has shown clinically meaningful progression-free survival in EGFR T790M-positive disease, putting it in the same therapeutic class as other third-generation EGFR inhibitors, although cross-trial comparisons with global standards such as osimertinib are complicated by differences in study design and patient populations. Independent oncology reviews in China highlight that Ameile’s safety profile is broadly consistent with expectations for an EGFR inhibitor, with rash and diarrhea among the most frequently observed adverse events and interstitial lung disease reported as a serious but relatively uncommon risk. The drug’s development has allowed oncologists in China to keep more patients on targeted therapy after resistance to first- and second-generation EGFR inhibitors, instead of moving immediately to chemotherapy.

Ameile is available as film-coated tablets for oral administration, enabling use both in hospital oncology departments and for home treatment when clinicians consider it appropriate, which aligns with a broader policy drive in China to support outpatient management of chronic cancer care. Chinese reimbursement decisions have also been important: listing within national or provincial reimbursement schemes can significantly reduce the out-of-pocket cost for patients, and Ameile’s inclusion in key formularies has helped expand access even as newer targeted drugs arrive. Analysts covering the Chinese oncology market note that price negotiations with authorities typically trade lower per-tablet pricing for higher volume, a dynamic that shapes Ameile’s commercial trajectory today.

Competition is intensifying, however, as multiple domestic and international drug makers push forward next-wave EGFR inhibitors and antibody-drug conjugates targeting a range of resistance mechanisms beyond T790M, often with ambitions in earlier treatment lines rather than only post-resistance settings. A recent market analysis of EGFR inhibitors projects mid-single to high-single-digit annual growth globally over the coming decade, driven by the expected launch of new tyrosine kinase inhibitors and combination strategies with immunotherapies, and it explicitly lists several emerging agents that could challenge existing third-generation options in selected segments. An EGFR inhibitor market forecast underscores how next-generation TKIs and antibody-drug conjugates are expected to capture growing patient share.

Within Hansoh Pharma’s portfolio, Ameile sits alongside a broader set of oncology and central nervous system drugs that collectively form the group’s main growth engine, reflecting the company’s strategic decision to concentrate R&D and commercial resources in these therapeutic areas rather than spread efforts thinly across many smaller indications. Income statements and management commentary from recent reporting periods show oncology products, including Ameile, contributing a substantial portion of prescription drug revenue, helping offset pricing pressure in other categories. Recent corporate disclosures emphasize that Hansoh continues to invest in clinical development programs aimed at label expansion, combination use and new biomarker-defined subgroups, all of which could extend Ameile’s lifecycle if trial results are positive.

China-focused broker research further points out that domestic oncology leaders are actively exploring partnerships with multinational companies and academic research centers to secure access to complementary mechanisms and geographic markets, and Hansoh is no exception as it evaluates alliances for both Ameile and pipeline candidates. In that context, Ameile is not just a revenue contributor but also a strategic proof point that the company can discover, develop and commercialize highly specialized oncology drugs in a competitive field that includes some of the world’s largest pharmaceutical firms, a capability that may influence future collaboration valuations.

As an established but still evolving asset within Hansoh’s oncology franchise, Ameile will likely face mounting pressure from new entrants and tightening reimbursement conditions, yet its installed prescribing base and clinical familiarity among Chinese oncologists give it a defensible starting point from which to adapt through potential label updates, pricing moves or combination strategies. Investors tracking the group’s progress will therefore pay close attention to upcoming clinical data and policy decisions affecting Ameile and related EGFR-targeted approaches. Shares of Hansoh Pharma’s parent entity, Hansoh Pharmaceutical Group Company Limited (ISIN KYG4232C1087), last traded on the Hong Kong Stock Exchange in Hong Kong dollars as part of the city’s healthcare sector benchmark, according to publicly available market data. Recent Hong Kong exchange filings provide the latest official share price and disclosure information.

Hansoh’s Ameile in brief: key product facts

• Product: Ameile (almonertinib)
• Manufacturer: Hansoh Pharmaceutical Group Company Limited
• Category: New Release/Launch - targeted oncology therapy
• Launch date: Initially approved in China in 2020 for EGFR T790M-positive NSCLC
• MSRP / Price: Priced in Chinese yuan with reimbursement-driven discounts; exact retail cost varies by province and insurance coverage
• Availability: Prescription-only in China, primarily through hospital oncology departments and authorized pharmacies
• Target audience: Adult patients with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer as defined in the Chinese label
• Key differentiator / USP: Third-generation EGFR inhibitor developed in China, tailored to local clinical practice and reimbursement structures

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.